| pubmed-article:18947822 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0013384 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0392702 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0596235 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0439799 | lld:lifeskim |
| pubmed-article:18947822 | lifeskim:mentions | umls-concept:C0604267 | lld:lifeskim |
| pubmed-article:18947822 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18947822 | pubmed:dateCreated | 2009-2-24 | lld:pubmed |
| pubmed-article:18947822 | pubmed:abstractText | Chronic L-3,4-dihydroxyphenylalanine (L-DOPA) treatment of Parkinson's disease (PD) leads to debilitating involuntary movements, termed L-DOPA-induced dyskinesia. Striatofugal medium spiny neurons (MSN) lose their dendritic spines and cortico-striatal glutamatergic synapses in PD and in experimental models of DA depletion. This loss of connectivity is triggered by a dysregulation of intraspine Cav1.3 L-type Ca2+ channels. Here we address the possible implication of DA denervation-induced spine pruning in the development of L-DOPA-induced dyskinesia. | lld:pubmed |
| pubmed-article:18947822 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18947822 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18947822 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18947822 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:18947822 | pubmed:issn | 1873-2402 | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:SchusterStefa... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:CenciM... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:BezardErwanE | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:SurmeierD... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:BlochBertrand... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:IttrichCarina... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:HengererBasti... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:AubertIncarna... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:DoudnikoffEve... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:RylanderDanie... | lld:pubmed |
| pubmed-article:18947822 | pubmed:author | pubmed-author:BerthetAmandi... | lld:pubmed |
| pubmed-article:18947822 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18947822 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18947822 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:18947822 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18947822 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18947822 | pubmed:pagination | 518-26 | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:meshHeading | pubmed-meshheading:18947822... | lld:pubmed |
| pubmed-article:18947822 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:18947822 | pubmed:articleTitle | Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. | lld:pubmed |
| pubmed-article:18947822 | pubmed:affiliation | Boehringer Ingelheim Pharma GmbH & Company KG, Biberach, Germany. | lld:pubmed |
| pubmed-article:18947822 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:29716 | entrezgene:pubmed | pubmed-article:18947822 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18947822 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18947822 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18947822 | lld:pubmed |
